Amplyx Pharmaceuticals Gets $67M

San Diego-based Amplyx Pharmaceuticals, which develops antifungal agents aimed at treating fungal infections, has raised $67M in a series C funding. The funding was led by Sofinnova Venture Partners, and also included Lundbeckfonden Ventures, Arix Bioscience and Pappas Capital, along with New Enterprise Associates, RiverVest Venture Partners, 3x5 RiverVest II and BioMed Ventures. As part of he funding, Sofinnova's Anand Mehra, M.D. and Lundbeckfonden's Johan Kordel, Ph.D., have both joined the company's board. Amplyx Pharmaceuticals, led by Ciara Kennedy, Ph.D., is developing antifungal agents aimed at treating fungal infections such as invasive aspergillosis and invasive candidiasis. The company has now raised $118.5M in total. More information »